相关实验视频

Updated: Jul 27, 2025

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.5K

TL-532,一种新型的特异性Toll-like受体3激动剂,合理设计用于向癌症:发现过程和生物特征

Sylvain Thierry1, Sarah Maadadi1, Aurore Berton1

  • 1TOLLYS SAS, 60F avenue Rockefeller, Lyon, France; Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.

Microbial cell (Graz, Austria)
|June 5, 2023
PubMed
概括

研究人员发现TL-532,一种新型双链RNA (dsRNA),可以激活Toll类受体3 (TLR3). 这种强大的TLR3激动剂通过诱导瘤细胞死亡而不会损害正常细胞,显示出作为向癌症治疗的前景.

关键词:
收费类受体3 收费类受体3激进分子的激进分子.灭症 (apoptosis) 是一种死亡的过程.癌症治疗疗法 癌症治疗这是一种炎症炎症炎症炎症.

更多相关视频

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.4K
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.5K

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K